Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Assessment of ALD403 in Chronic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of migraine at ≤ 35 years of age with history of chronic migraine ≥ 1 year~* During the 28 day screening period, must have ≥ 15 headache days of which ≥ 8 days were assessed as migraine days with at least 5 migraine attacks as recorded in the eDiary~* Headache eDiary was completed on at least 22 of the 28 days prior to randomization~Exclusion Criteria:~* Confounding pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome) or any pain syndrome that requires regular analgesia~* Psychiatric conditions that are uncontrolled and untreated, including conditions that are not controlled for a minimum of 6 months prior to screening.~* History or diagnosis of complicated migraine (ICHD-III beta version, 2013), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, migraine with brainstem aura, sporadic and familial hemiplegic migraine~* Unable to differentiate migraine from other headaches~* Subject has received botulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections in the head, face, or neck within 4 months prior to screening.~* Have any clinically significant concurrent medical condition~* Receipt of any monoclonal antibody treatment within 6 months of screening (within or outside a clinical trial)~* Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- ALD403 Dose Level 1 (Type: EXPERIMENTAL): ALD403 Dose Level 1 (IV)
- ALD403 Dose Level 2 (Type: EXPERIMENTAL): ALD403 Dose Level 2 (IV)
- ALD403 Dose Level 3 (Type: EXPERIMENTAL): ALD403 Dose Level 3 (IV)
- ALD403 Dose Level 4 (Type: EXPERIMENTAL): ALD403 Dose Level 4 (IV)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (IV)

Based on this trial design, predict the completion outcome and termination type (if applicable).